Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Gets USPTO Nod on Claims for Use of miRNAs in Gene-Expression Analysis

Premium

Asuragen said last week that it has received a notice of allowance from the US Patent and Trademark Office for a patent application related to the use of microRNAs as normalizers in gene-expression studies.

“Data normalization is necessary to control for sample variability that can adversely affect the accurate quantification of gene expression,” the company said. “Improper normalization can affect the magnitude and even the direction of change in miRNA gene expression in diseased clinical samples, such as tumor specimens, and is critical for the development of robust and reliable research and diagnostic assays.

Asuragen said that studies have validated the use of the use of “numerous different endogenous miRNAs for normalization with a variety of tissue and sample types,” which are particularly useful for gene-expression measurement techniques employing RT-qPCR.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.